Drugs / NGM313
Trials 3 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT03298464 | Sep 2017 → Jun 2018 | obesity disorder | NGM Biopharmaceuticals, Inc | Completed | No outcome recorded |
| Phase 1 | NCT02708576 | Feb 2016 → Apr 2017 | obesity disorder | NGM Biopharmaceuticals, Inc | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT04583423 | Nov 2020 → Apr 2023 | metabolic dysfunction-associated steatohepatitis | Merck Sharp & Dohme LLC | Terminated | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | NGM313 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02708576 ↗ |
| Known as | MK-3655 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04583423 ↗ |
| Action | Activate | “selectively activates the FGFR1c/β-klotho co-receptor complex” PMID 39984821 ↗ Feb 2025 |
| Modality | Monoclonal antibody | “MK-3655, a monoclonal antibody” PMID 39984821 ↗ Feb 2025 |
| Route | Subcutaneous | “Subcutaneous injection” NCT03298464 ↗ |